Clinical trials form an integral part of the overall drug development process, enabling the necessary evaluation of the safety and efficacy of a drug candidate. As these trials are prone to delays, and can even fail altogether, they impose an immense financial pressure on sponsors. Studies suggest that around 40% of the total investment made for the development of a drug candidate is dedicated to clinical trials. However, the conduct of such trials is often fraught with challenges, including sci
...read moreMessenger ribonucleic acid (mRNA) is a type of single-stranded ribonucleic acid (RNA), which helps in transferring genetic information in order to produce proteins. The mRNA encoding instructions for protein synthesis are transferred from a strand of DNA to the ribosomes, where these instructions are translated and processed into functional proteins. Q1. How is the research and development (R&D) activity evolving in the mRNA-based drugs industry? mRNA therapeutics and mRNA vacci
...read moreThe cancer is the one of the leading cause of deaths, globally. In fact, as per the World Health Organization (WHO), 10 million cancer related deaths were reported in 2020. Further, it is estimated that, by the end of 2040, 27.5 million new cases will be added to the global cancer burden, exerting tremendous physical, emotional and financial strain on affected individuals, their families, communities as well as the national health systems. Even though a number of treatment options are available
...read moreThe global bacteriophage therapy market is projected to grow from USD 74 million in 2022 to USD 193 million by 2035, exhibiting a CAGR of 8% during forecast period Antimicrobial resistance (AMR) has been identified as one of the greatest threats to public health. According to the Centers of Disease Control and Prevention, more than 2.8 million cases of AMR infections are identified in the United States on an annual basis, leading to death of more than 35,000 people. Further, World Health Orga
...read moreMore than 10,000 unique species of microorganisms make up the human microbiome; in fact, the total number of microbial cells in the human body is known to vastly outnumber the indigenous cellular population. Of late, many studies have demonstrated the importance of microbiome and its profound influence on multiple biological functions. Moreover, it has been shown that the diversity of the microbial community residing in a host body varies based on both intrinsic (gender, genetics, and immunity)
...read moreThe term rare kidney diseases represents around 150 different indications. It is worth highlighting that the prevalence rate of rare kidney disorders (RKD) is estimated to be 60-80 per 100,000 cases / individuals in the US and Europe. Despite their relatively low prevalence, these set of indications are believed to be one of the leading causes of renal diseases, along with diabetes and other rare genetic kidney disorders. The low disease incidence rate of such disorders, coupled to the lack of a
...read moreAided by the ongoing advancements in clinical pharmacology and oncology research, as well as the rising demand for targeted therapies, high potency active pharmaceutical ingredients (HPAPIs) and cytotoxic drugs have emerged as one of the key areas of interest for researchers and drug developers worldwide. As is well known, HPAPIs are pharmacologically active compounds which are capable of eliciting a biological response even at extremely low concentrations. Specifically, HPAPIs are categorized o
...read moreThe global self testing kits market is projected to grow from USD 14.8 billion in 2022 to USD 31 billion by 2035, exhibiting a CAGR of 6% during forecast period Since the approval of the first over-the-counter test kits in the early 1976, there has been a substantial increase in the development initiatives focused on such products. In this context, it is worth highlighting that over 20 million at-home pregnancy test kits are being annually sold in the US. Companies have also developed at-home
...read moreThe global antiviral drugs market is projected to grow from USD 57 billion in 2022 to USD 127 billion by 2035, exhibiting a CAGR of 6.3% during forecast period Infectious diseases are known to be one of the top 10 leading causes of deaths, worldwide. In-fact, more than 40 million people are affected by various types of infectious diseases annually. An article published in The Lancet journal reported that COVID-19 alone caused death of over 18 million people in 2020. Further, it has been
...read moreThe global nutrigenomics market is projected to grow from USD 0.64 billion in 2022 to USD 3 billion by 2035, exhibiting a CAGR of 13% during forecast period Given the recent shift from the one-size-fits-all model to a more personalized mode of treatment, there has been a growing interest in identification and adoption of novel techniques. It is estimated that there are around 20,000 genes present in the human body, all of which interact with the nutrients in the food, either directly or indir
...read moreGlobally, cancer is one of the leading causes of death; in 2020, about 10 million cancer related deaths were reported. Further, according to a study published in American Cancer Society Journal, by 2040, the number of cancer cases is projected to reach over 28 million, indicating a cumulative growth of nearly 47%, since 2020. The continuous growth in the number of cancer patients imposes a huge burden, in terms of finances as well as resources, on the overall healthcare system. In this con
...read moreCell and gene therapy candidates have been demonstrated to have the potential to treat complex and rare diseases, including indications, for which no effective treatment is currently available. In this context, it is important to mention that, in case of cell therapy, human cells are transplanted to repair or replace the damaged cells / tissues, thereby, enabling their treatment through alteration or restoration of certain sets of cells. The cells may originate from the patient (autologous cells
...read moreOver the last few decades, the development landscape of small molecule drugs has been significantly impacted by various biotechnology breakthroughs. Further, with the advent of novel technologies, biologics have made a significant impact in the pharmaceutical domain, delivering ground-breaking treatment for a myriad of disease indications, including immunological, oncological and rare disorders. In this context, it is worth highlighting those 14 biopharmaceutical products (including cell therapi
...read moreThe global RNA sequencing market is projected to grow from USD 2.8 billion in 2022 to USD 7.5 billion by 2035, exhibiting a CAGR of 8% during forecast period RNA sequencing was first introduced by Fredrick Sanger in 1977, who used chain termination method, also known sanger sequencing method / first generation sequencing method. It is a rapid method that enables profiling of whole range of RNA expressed by the cell, with increased coverage and resolution. However, the sanger sequencing method
...read moreThe organ on a chip market is projected to grow from USD 96 million in 2022 to USD 1.2 billion by 2035, exhibiting a CAGR of 21% during forecast period It is a well-known fact that almost 90% of the therapeutic interventions fail in clinical trials, resulting in significant economic losses to the pharmaceutical industry. The lack of effective preclinical prediction of drug responses in humans is one of the various reasons for drug’s failure to get approved. Animal testing for prec
...read moreCancer is known to be one of the leading causes of deaths, worldwide. In fact, as per the annual statistics reported by the American Cancer Society (ACS) indicate that, in 2022, around 1.9 million individuals are likely to be diagnosed with various types of cancer in the US. Further, it is estimated that, by the end of 2040, 27.5 million new cancer cases will be added to the global numbers, exerting tremendous physical, emotional and financial strain on affected individuals, their families, comm
...read moreThe global AAV vectors market is projected to grow from USD 1.9 billion in 2022 to USD 11.1 billion by 2035, exhibiting a CAGR of 14% during forecast period Given the potential of gene therapies in targeting the underlying cause of a disease at cellular level, the demand for such therapies has increased considerably over the past few years. Currently, more than 285 gene therapies are being evaluated in different phases of clinical development. Further, various gene therapy developers ha
...read moreThe global manufacturing execution systems market is projected to grow from USD 3 billion in 2022 to USD 20.4 billion by 2035, exhibiting a CAGR of 16% during forecast period Every year, the healthcare industry generates a massive amount of data. In fact, the healthcare data currently constitutes around 30% share of the global data volume. Further, it is estimated that, by 2025, the data generated via the healthcare sector will rise at an annualized growth rate of 36%. However, it is importan
...read moreThe global combination products services market is projected to grow from USD 252 million in 2022 to USD 938 million by 2035, exhibiting a CAGR of 10% during forecast period Non-adherence to prescribed medication regimen is one of the major factors that not only causes negative implications on the patient’s health, but also adds to the overall pharmaceutical industry’s burden. According to an article published by Contract Pharma in April 2022, non-adherence to prescribed medicines
...read moreCancer is the one of the leading cause of deaths, globally, as per the World Health Organization (WHO). Annual statistics reported by the American Cancer Society (ACR) indicate that, in 2022, around 1.9 million individuals are likely to be diagnosed with various types of cancer in the US. During the same year, around 0.6 million cancer-related deaths are anticipated to be reported in the aforementioned region. In this context, it is important to highlight that, according to the International Age
...read moreWe are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry